A Phase 1 interventional study of TAK-117 in Metastatic Solid Tumors, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-09.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine the maximum tolerated dose (MTD) and/or optimal biologic dose(OBD), safety and tolerability, dose-limiting toxicity (DLT) of TAK-117 when administered orally in subjects with advanced solid malignancies.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 125 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-117 administered once a day orally
Drug: TAK-117
TAK-117 administered orally intermittently, once every other day (Monday, Wednesday, and Friday) each week
Drug: TAK-117
TAK-117 administered orally intermittently, once a day for 3 consecutive days (Monday, Tuesday, and Wednesday) each week
Drug: TAK-117
oral administration of TAK-117, daily and intermittent schedules.
Maximum Tolerated Dose (MTD) of TAK-117
MTD is highest dose level of TAK-117 at which no more than 1 out of 6 participants had a dose limiting toxicity (DLT) during first cycle. DLT was any 1 of following events occurring within first 21 days of Cycle 1 of TAK-117 administration, Grade 2: fasting hyperglycemia for \>14 days. Grade 3: nausea and/or vomiting/diarrhea for \>7 days; rash for \>7 days; thrombocytopenia with bleeding; fasting hyperglycemia for \>24 hours(hr). Grade \>=3:nonhematologic toxicity considered clinically significant by investigator. Grade 4:neutropenia (absolute neutrophil count \<=0.5\*10\^9per liter\[/L\]) for \>7 days in absence of growth factor support; neutropenia of any duration accompanied with fever \>=38.5 degree Celsius and/or systemic infection. Grade \>=4:hematologic toxicity. Inability to administer at least 75% of planned doses of TAK-117 within Cycle 1 due to its related toxicity;Any clinically significant occurrence that investigators and sponsor agreed would place participants at undue safety risk.
Time frame: Baseline up to Cycle 1 Day 21
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Death, Adverse Events (AEs) Leading to Discontinuation of Study Drug, and DLTs in Cycle 1
Time frame: Baseline up to Cycle 27 Day 45
Number of Participants With Highest Level of TEAEs Severity
Severity of AEs was evaluated based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0 as follow: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (life-threatening); Grade 5 (fatal).
Time frame: Baseline up to Cycle 27 Day 45
Number of Participants With Clinically Meaningful Changes in Laboratory Values
Time frame: Baseline up to Cycle 27 Day 45
Number of Participants With Clinically Meaningful Changes in Vital Signs
Time frame: Baseline up to Cycle 27 day 45
Number of Participants With Clinically Meaningful Changes in Electrocardiogram (ECG)
Time frame: Baseline up to Cycle 27 Day 45
Overall Response Rate (ORR)
The estimate of the ORR is calculated as crude percentage of participants who's best overall response is complete response (CR) or partial response (PR). Objective response (CR and PR) as determined by the participants best tumor response was assessed using response evaluation criteria in solid tumors (RECIST) version 1.1. As per RECIST version 1.1, CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 millimeter \[mm\]). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. Stable disease was defined as not qualifying for CR, PR, and progressive disease (PD).
Time frame: Cycle 1 Day 8 up to Cycle 27 Day 1 or disease progression or death
Duration of Objective Response
Duration of response was to be calculated for participants who achieved CR or PR. Duration of objective response was defined as the number of days from the start date of PR or CR (whichever response was achieved first) to the first date that PD or disease progression was objectively documented. The duration of objective response was to be right-censored for participants who achieved CR or PR and met 1 of the following conditions: Non-protocol anticancer treatment started before documentation of PD; Documented PD after more than 1 missed disease assessment visit; Alive and did not have documentation of PD before a data analysis cutoff date.
Time frame: Cycle 1 Day 8 up to Cycle 27 Day 1 or disease progression or death
Clinical Benefit Rate (CBR)
Clinical benefit rate was defined as the participants who achieved stable disease (SD) for at least 15 weeks, CR, or PR. The estimate of the CBR was calculated as crude percentage of participants whose best ORR was CR, PR or SD for at least 90 days.
Time frame: Cycle 1 Day 8 up to Cycle 27 Day 1 or disease progression or death
Cmax: Maximum Observed Plasma Concentration for TAK-117
Time frame: Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
Ctrough: Observed Concentration at the End of Dosing Interval for TAK-117
Time frame: Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-117
Time frame: Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
T 1/2z: Terminal Disposition Phase Half-life for TAK-117
Time frame: Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-117
Time frame: Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-117
Time frame: Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
%AUC Extrapolated: Percentage of Area Under Concentration-extrapolated
Time frame: Process A: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 24 hrs) post-dose; Process B: Cycle 1 Day 1 pre-dose and at multiple timepoints (up to 48 hrs) post-dose
Percent Change From Baseline in Pharmacodynamic Markers
Pharmacodynamic markers included phosphorylated ribosomal protein S6 (PS6), phosphorylated eukaryotic initiation factor 4E-binding protein 1 (P4EBP1), phosphorylated N-myc downstream regulated gene 1 (PNDRG1), phosphorylated proline-rich AKT substrate of 40 kilodaltons (PPRAS40), and phosphorylated serine/threonine protein kinase AKT (PAKT). Analysis population (n) for each skin biopsy biomarker is as follow: P4EBP1 (n=6,6,6,2,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0); PAKT and PNDRG1 (n=6,6,7,2,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0); PPRAS40 (n= 6,0,6,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0); PS6 (n=6,6,7,2,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0)."n" for each tumor tissue biomarkers is as follow: P4EBP1, PAKT, PNDRG1, and PS6 (n=1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0); PPRAS40 (n= 1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0).
Time frame: Cycle 1 Day 8
Participants took part in the study at 5 investigative sites in England, Spain and the United States from 06 October 2011 to 15 January 2016.
| Milestone | Process A: TAK-117 100 Milligram (mg), Once Daily (QD) | Process A: TAK-117 150 mg, QD | Process A: TAK-117 200 mg, QD | Process A: TAK-117 300 mg, QD | Process A: TAK-117 200 mg, MWF QW | Process A: TAK-117 300 mg, MWF QW | Process A: TAK-117 400 mg, MWF QW | Process A: TAK-117 600 mg, MWF QW | Process A: TAK-117 900 mg, MWF QW | Process A: TAK-117 1200 mg, MWF QW | Process A: TAK-117 200 mg, MTW QW | Process A: TAK-117 400 mg, MTW QW | Process A: TAK-117 600 mg, MTW QW | Process A: TAK-117 900 mg, MTW QW | Process B: TAK-117 600 mg Process B Capsule (FM) MWF QW | Process B: TAK-117 900 mg FM MWF QW | Process B: TAK-117 1200 mg FM MWF QW | Process B: TAK-117 600 mg FM MTW QW | Process B: TAK-117 900 mg FM MTW QW | Process B: TAK-117 1200 mg FM MTW QW | Process B: TAK-117 1500 mg FM MTW QW | Process B: TAK-117 300 mg FM Twice Daily (BID) MWF QW | Process B: TAK-117 400 mg FM BID MWF QW | Process B: TAK-117 500 mg FM BID MWF QW | Process B: TAK-117 600 mg FM BID MWF QW |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 8 | 4 | 3 | 3 | 3 | 3 | 12 | 3 | 3 | 3 | 3 | 11 | 3 | 3 | 7 | 3 | 3 | 3 | 6 | 4 | 4 | 10 | 8 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 6 | 6 | 8 | 4 | 3 | 3 | 3 | 3 | 12 | 3 | 3 | 3 | 3 | 11 | 3 | 3 | 7 | 3 | 3 | 3 | 6 | 4 | 4 | 10 | 8 |
| Withdrew: Disease progression | 5 | 4 | 8 | 3 | 3 | 3 | 3 | 2 | 9 | 1 | 3 | 3 | 2 | 8 | 3 | 1 | 4 | 3 | 1 | 2 | 5 | 2 | 3 | 7 | 3 |
| Withdrew: Adverse event | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 3 |
| Withdrew: Participant decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 3 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Medication prohibited by protocol | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
MTD is highest dose level of TAK-117 at which no more than 1 out of 6 participants had a dose limiting toxicity (DLT) during first cycle. DLT was any 1 of following events occurring within first 21 days of Cycle 1 of TAK-117 administration, Grade 2: fasting hyperglycemia for \>14 days. Grade 3: nausea and/or vomiting/diarrhea for \>7 days; rash for \>7 days; thrombocytopenia with bleeding; fasting hyperglycemia for \>24 hours(hr). Grade \>=3:nonhematologic toxicity considered clinically significant by investigator. Grade 4:neutropenia (absolute neutrophil count \<=0.5\*10\^9per liter\[/L\]) for \>7 days in absence of growth factor support; neutropenia of any duration accompanied with fever \>=38.5 degree Celsius and/or systemic infection. Grade \>=4:hematologic toxicity. Inability to administer at least 75% of planned doses of TAK-117 within Cycle 1 due to its related toxicity;Any clinically significant occurrence that investigators and sponsor agreed would place participants at undue safety risk.
| mg | Process A: Total QD TAK-117 100-300 mg | Process A: Total MWF QW 200-1200 mg | Process A: Total MTW QW 200-900 mg | Process B: Total FM MWF QW TAK-117 600-1200 mg | Process B: Total FM MTW QW 600-1500 mg | Process B: Total FM BID MWF QW 300-600 mg |
|---|---|---|---|---|---|---|
| Maximum Tolerated Dose (MTD) of TAK-117 | 150 | 900 | 900 | NA | NA | 500 |
| participants | Process A: TAK-117 100 Milligram (mg), Once Daily (QD) | Process A: TAK-117 150 mg, QD | Process A: TAK-117 200 mg, QD | Process A: TAK-117 300 mg, QD | Process A: TAK-117 200 mg, MWF QW | Process A: TAK-117 300 mg, MWF QW | Process A: TAK-117 400 mg, MWF QW | Process A: TAK-117 600 mg, MWF QW | Process A: TAK-117 900 mg, MWF QW | Process A: TAK-117 1200 mg, MWF QW | Process A: TAK-117 200 mg, MTW QW | Process A: TAK-117 400 mg, MTW QW | Process A: TAK-117 600 mg, MTW QW | Process A: TAK-117 900 mg, MTW QW | Process B: TAK-117 600 mg Process B Capsule (FM) MWF QW | Process B: TAK-117 900 mg FM MWF QW | Process B: TAK-117 1200 mg FM MWF QW | Process B: TAK-117 600 mg FM MTW QW | Process B: TAK-117 900 mg FM MTW QW | Process B: TAK-117 1200 mg FM MTW QW | Process B: TAK-117 1500 mg FM MTW QW | Process B: TAK-117 300 mg FM Twice Daily (BID) MWF QW | Process B: TAK-117 400 mg FM BID MWF QW | Process B: TAK-117 500 mg FM BID MWF QW | Process B: TAK-117 600 mg FM BID MWF QW |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TEAE | 6 | 6 | 8 | 4 | 3 | 3 | 3 | 3 | 12 | 3 | 3 | 3 | 3 | 11 | 3 | 3 | 7 | 3 | 3 | 3 | 6 | 3 | 4 | 10 | 7 |
| SAE | 2 | 3 | 4 | 2 | 0 | 2 | 0 | 2 | 5 | 2 | 0 | 1 | 0 | 7 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 5 | 5 |
| AEs leading to discontinuation of study drug | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 4 |
| Death | 0 | 1 | 2 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 |
| DLTs in Cycle 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
Severity of AEs was evaluated based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0 as follow: Grade 1 (mild); Grade 2 (moderate); Grade 3 (severe); Grade 4 (life-threatening); Grade 5 (fatal).
| participants | Process A: TAK-117 100 Milligram (mg), Once Daily (QD) | Process A: TAK-117 150 mg, QD | Process A: TAK-117 200 mg, QD | Process A: TAK-117 300 mg, QD | Process A: TAK-117 200 mg, MWF QW | Process A: TAK-117 300 mg, MWF QW | Process A: TAK-117 400 mg, MWF QW | Process A: TAK-117 600 mg, MWF QW | Process A: TAK-117 900 mg, MWF QW | Process A: TAK-117 1200 mg, MWF QW | Process A: TAK-117 200 mg, MTW QW | Process A: TAK-117 400 mg, MTW QW | Process A: TAK-117 600 mg, MTW QW | Process A: TAK-117 900 mg, MTW QW | Process B: TAK-117 600 mg Process B Capsule (FM) MWF QW | Process B: TAK-117 900 mg FM MWF QW | Process B: TAK-117 1200 mg FM MWF QW | Process B: TAK-117 600 mg FM MTW QW | Process B: TAK-117 900 mg FM MTW QW | Process B: TAK-117 1200 mg FM MTW QW | Process B: TAK-117 1500 mg FM MTW QW | Process B: TAK-117 300 mg FM Twice Daily (BID) MWF QW | Process B: TAK-117 400 mg FM BID MWF QW | Process B: TAK-117 500 mg FM BID MWF QW | Process B: TAK-117 600 mg FM BID MWF QW |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade 1 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Grade 2 | 3 | 4 | 2 | 1 | 1 | 2 | 2 | 2 | 5 | 0 | 2 | 2 | 2 | 1 | 1 | 1 | 3 | 3 | 0 | 0 | 3 | 1 | 1 | 4 | 1 |
| Grade 3 | 2 | 1 | 3 | 1 | 0 | 0 | 1 | 0 | 5 | 3 | 1 | 1 | 1 | 7 | 1 | 1 | 3 | 0 | 2 | 1 | 3 | 1 | 2 | 3 | 4 |
| Grade 4 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 |
| Grade 5 | 0 | 1 | 2 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 |
| participants | Process A: TAK-117 100 Milligram (mg), Once Daily (QD) | Process A: TAK-117 150 mg, QD | Process A: TAK-117 200 mg, QD | Process A: TAK-117 300 mg, QD | Process A: TAK-117 200 mg, MWF QW | Process A: TAK-117 300 mg, MWF QW | Process A: TAK-117 400 mg, MWF QW | Process A: TAK-117 600 mg, MWF QW | Process A: TAK-117 900 mg, MWF QW | Process A: TAK-117 1200 mg, MWF QW | Process A: TAK-117 200 mg, MTW QW | Process A: TAK-117 400 mg, MTW QW | Process A: TAK-117 600 mg, MTW QW | Process A: TAK-117 900 mg, MTW QW | Process B: TAK-117 600 mg Process B Capsule (FM) MWF QW | Process B: TAK-117 900 mg FM MWF QW | Process B: TAK-117 1200 mg FM MWF QW | Process B: TAK-117 600 mg FM MTW QW | Process B: TAK-117 900 mg FM MTW QW | Process B: TAK-117 1200 mg FM MTW QW | Process B: TAK-117 1500 mg FM MTW QW | Process B: TAK-117 300 mg FM Twice Daily (BID) MWF QW | Process B: TAK-117 400 mg FM BID MWF QW | Process B: TAK-117 500 mg FM BID MWF QW | Process B: TAK-117 600 mg FM BID MWF QW |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Meaningful Changes in Laboratory Values | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| participants | Process A: TAK-117 100 Milligram (mg), Once Daily (QD) | Process A: TAK-117 150 mg, QD | Process A: TAK-117 200 mg, QD | Process A: TAK-117 300 mg, QD | Process A: TAK-117 200 mg, MWF QW | Process A: TAK-117 300 mg, MWF QW | Process A: TAK-117 400 mg, MWF QW | Process A: TAK-117 600 mg, MWF QW | Process A: TAK-117 900 mg, MWF QW | Process A: TAK-117 1200 mg, MWF QW | Process A: TAK-117 200 mg, MTW QW | Process A: TAK-117 400 mg, MTW QW | Process A: TAK-117 600 mg, MTW QW | Process A: TAK-117 900 mg, MTW QW | Process B: TAK-117 600 mg Process B Capsule (FM) MWF QW | Process B: TAK-117 900 mg FM MWF QW | Process B: TAK-117 1200 mg FM MWF QW | Process B: TAK-117 600 mg FM MTW QW | Process B: TAK-117 900 mg FM MTW QW | Process B: TAK-117 1200 mg FM MTW QW | Process B: TAK-117 1500 mg FM MTW QW | Process B: TAK-117 300 mg FM Twice Daily (BID) MWF QW | Process B: TAK-117 400 mg FM BID MWF QW | Process B: TAK-117 500 mg FM BID MWF QW | Process B: TAK-117 600 mg FM BID MWF QW |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Meaningful Changes in Vital Signs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| participants | Process A: TAK-117 100 Milligram (mg), Once Daily (QD) | Process A: TAK-117 150 mg, QD | Process A: TAK-117 200 mg, QD | Process A: TAK-117 300 mg, QD | Process A: TAK-117 200 mg, MWF QW | Process A: TAK-117 300 mg, MWF QW | Process A: TAK-117 400 mg, MWF QW | Process A: TAK-117 600 mg, MWF QW | Process A: TAK-117 900 mg, MWF QW | Process A: TAK-117 1200 mg, MWF QW | Process A: TAK-117 200 mg, MTW QW | Process A: TAK-117 400 mg, MTW QW | Process A: TAK-117 600 mg, MTW QW | Process A: TAK-117 900 mg, MTW QW | Process B: TAK-117 600 mg Process B Capsule (FM) MWF QW | Process B: TAK-117 900 mg FM MWF QW | Process B: TAK-117 1200 mg FM MWF QW | Process B: TAK-117 600 mg FM MTW QW | Process B: TAK-117 900 mg FM MTW QW | Process B: TAK-117 1200 mg FM MTW QW | Process B: TAK-117 1500 mg FM MTW QW | Process B: TAK-117 300 mg FM Twice Daily (BID) MWF QW | Process B: TAK-117 400 mg FM BID MWF QW | Process B: TAK-117 500 mg FM BID MWF QW | Process B: TAK-117 600 mg FM BID MWF QW |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Meaningful Changes in Electrocardiogram (ECG) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The estimate of the ORR is calculated as crude percentage of participants who's best overall response is complete response (CR) or partial response (PR). Objective response (CR and PR) as determined by the participants best tumor response was assessed using response evaluation criteria in solid tumors (RECIST) version 1.1. As per RECIST version 1.1, CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 millimeter \[mm\]). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. Stable disease was defined as not qualifying for CR, PR, and progressive disease (PD).
| percentage of participants | Process A: TAK-117 100 Milligram (mg), Once Daily (QD) | Process A: TAK-117 150 mg, QD | Process A: TAK-117 200 mg, QD | Process A: TAK-117 300 mg, QD | Process A: TAK-117 200 mg, MWF QW | Process A: TAK-117 300 mg, MWF QW | Process A: TAK-117 400 mg, MWF QW | Process A: TAK-117 600 mg, MWF QW | Process A: TAK-117 900 mg, MWF QW | Process A: TAK-117 1200 mg, MWF QW | Process A: TAK-117 200 mg, MTW QW | Process A: TAK-117 400 mg, MTW QW | Process A: TAK-117 600 mg, MTW QW | Process A: TAK-117 900 mg, MTW QW | Process B: TAK-117 600 mg Process B Capsule (FM) MWF QW | Process B: TAK-117 900 mg FM MWF QW | Process B: TAK-117 1200 mg FM MWF QW | Process B: TAK-117 600 mg FM MTW QW | Process B: TAK-117 900 mg FM MTW QW | Process B: TAK-117 1200 mg FM MTW QW | Process B: TAK-117 1500 mg FM MTW QW | Process B: TAK-117 300 mg FM Twice Daily (BID) MWF QW | Process B: TAK-117 400 mg FM BID MWF QW | Process B: TAK-117 500 mg FM BID MWF QW | Process B: TAK-117 600 mg FM BID MWF QW |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Response Rate (ORR) | 0 (0.00 to 60.24) | 0 (0.00 to 45.93) | 13 (0.32 to 52.65) | 100 (15.81 to 100.00) | 0 (0.00 to 70.76) | 0 (0.00 to 70.76) | 0 (0.00 to 70.76) | 0 (0.00 to 70.76) | 0 (0.00 to 30.85) | 0 (0.00 to 70.76) | 0 (0.00 to 70.76) | 0 (0.00 to 70.76) | 0 (0.00 to 97.50) | 0 (0.00 to 33.63) | 0 (0.00 to 70.76) | 0 (0.00 to 97.50) | 0 (0.00 to 52.18) | 0 (0.00 to 70.76) | 0 (0.00 to 84.19) | 0 (0.00 to 70.76) | 0 (0.00 to 52.18) | 0 (0.00 to 70.76) | 0 (0.00 to 70.76) | 0 (0.00 to 36.94) | 25 (0.63 to 80.59) |
Duration of response was to be calculated for participants who achieved CR or PR. Duration of objective response was defined as the number of days from the start date of PR or CR (whichever response was achieved first) to the first date that PD or disease progression was objectively documented. The duration of objective response was to be right-censored for participants who achieved CR or PR and met 1 of the following conditions: Non-protocol anticancer treatment started before documentation of PD; Documented PD after more than 1 missed disease assessment visit; Alive and did not have documentation of PD before a data analysis cutoff date.
No measurements were reported for this outcome.
Clinical benefit rate was defined as the participants who achieved stable disease (SD) for at least 15 weeks, CR, or PR. The estimate of the CBR was calculated as crude percentage of participants whose best ORR was CR, PR or SD for at least 90 days.
| percentage of participants | Process A: TAK-117 100 Milligram (mg), Once Daily (QD) | Process A: TAK-117 150 mg, QD | Process A: TAK-117 200 mg, QD | Process A: TAK-117 300 mg, QD | Process A: TAK-117 200 mg, MWF QW | Process A: TAK-117 300 mg, MWF QW | Process A: TAK-117 400 mg, MWF QW | Process A: TAK-117 600 mg, MWF QW | Process A: TAK-117 900 mg, MWF QW | Process A: TAK-117 1200 mg, MWF QW | Process A: TAK-117 200 mg, MTW QW | Process A: TAK-117 400 mg, MTW QW | Process A: TAK-117 600 mg, MTW QW | Process A: TAK-117 900 mg, MTW QW | Process B: TAK-117 600 mg Process B Capsule (FM) MWF QW | Process B: TAK-117 900 mg FM MWF QW | Process B: TAK-117 1200 mg FM MWF QW | Process B: TAK-117 600 mg FM MTW QW | Process B: TAK-117 900 mg FM MTW QW | Process B: TAK-117 1200 mg FM MTW QW | Process B: TAK-117 1500 mg FM MTW QW | Process B: TAK-117 300 mg FM Twice Daily (BID) MWF QW | Process B: TAK-117 400 mg FM BID MWF QW | Process B: TAK-117 500 mg FM BID MWF QW | Process B: TAK-117 600 mg FM BID MWF QW |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Benefit Rate (CBR) | 25 (0.63 to 80.59) | 17 (0.42 to 64.12) | 38 (8.52 to 75.51) | 100 (15.81 to 100.00) | 33 (0.84 to 90.57) | 33 (0.84 to 90.57) | 33 (0.84 to 90.57) | 0 (0.00 to 70.76) | 20 (2.52 to 55.61) | 67 (9.43 to 99.16) | 0 (0.00 to 70.76) | 0 (0.00 to 70.76) | 0 (0.00 to 97.50) | 56 (21.20 to 86.30) | 33 (0.84 to 90.57) | 0 (0.00 to 97.50) | 0 (0.00 to 52.18) | 33 (0.84 to 90.57) | 0 (0.00 to 84.19) | 0 (0.00 to 70.76) | 0 (0.00 to 52.18) | 0 (0.00 to 70.76) | 33 (0.84 to 90.57) | 25 (3.19 to 65.09) | 25 (0.63 to 80.59) |
| nanogram per milliliter (ng/mL) | Process A: TAK-117 100 mg | Process A: TAK-117 150 mg | Process A: TAK-117 200 mg | Process A: TAK-117 300 mg | Process A: TAK-117 400 mg | Process A: TAK-117 600 mg | Process A: TAK-117 900 mg | Process A: TAK-117 1200 mg | Process B: TAK-117 300 mg | Process B: TAK-117 400 mg | Process B: TAK-117 500 mg | Process B: TAK-117 600 mg | Process B: TAK-117 900 mg | Process B: TAK-117 1200 mg | Process B: TAK-117 1500 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmax: Maximum Observed Plasma Concentration for TAK-117 | 1747.61 ± 48.7 | 1613.23 ± 58.5 | 2736.60 ± 36.4 | 2658.23 ± 90.0 | 4335.88 ± 42.5 | 4175.13 ± 82.4 | 7863.36 ± 42.1 | 8586.50 ± 53.6 | 1162.06 ± 117.5 | 1656.71 ± 77.0 | 2973.26 ± 53.3 | 3870.43 ± 61.1 | 6960.06 ± 69.3 | 6073.55 ± 53.2 | 6899.80 ± 67.9 |
| ng/mL | Process A: TAK-117 100 mg | Process A: TAK-117 150 mg | Process A: TAK-117 200 mg | Process A: TAK-117 300 mg | Process A: TAK-117 400 mg | Process A: TAK-117 600 mg | Process A: TAK-117 900 mg | Process A: TAK-117 1200 mg | Process B: TAK-117 300 mg | Process B: TAK-117 400 mg | Process B: TAK-117 500 mg | Process B: TAK-117 600 mg | Process B: TAK-117 900 mg | Process B: TAK-117 1200 mg | Process B: TAK-117 1500 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ctrough: Observed Concentration at the End of Dosing Interval for TAK-117 | 187.29 ± 102.1 | 177.70 ± 124.0 | 630.82 ± 70.0 | 627.62 ± 93.7 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| hr | Process A: TAK-117 100 mg | Process A: TAK-117 150 mg | Process A: TAK-117 200 mg | Process A: TAK-117 300 mg | Process A: TAK-117 400 mg | Process A: TAK-117 600 mg | Process A: TAK-117 900 mg | Process A: TAK-117 1200 mg | Process B: TAK-117 300 mg | Process B: TAK-117 400 mg | Process B: TAK-117 500 mg | Process B: TAK-117 600 mg | Process B: TAK-117 900 mg | Process B: TAK-117 1200 mg | Process B: TAK-117 1500 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-117 | 1.5 (1 to 4) | 1.5 (1 to 2) | 2.0 (1 to 4) | 2.1 (1 to 4) | 4.0 (1 to 8) | 3.1 (1 to 4) | 2.0 (1 to 8) | 5.8 (4 to 8) | 1.6 (1 to 4) | 4.0 (2 to 8) | 3.6 (2 to 6) | 3.4 (1 to 8) | 4.0 (1 to 8) | 4.0 (1 to 23) | 3.8 (2 to 8) |
| hrs | Process A: TAK-117 100 mg | Process A: TAK-117 150 mg | Process A: TAK-117 200 mg | Process A: TAK-117 300 mg | Process A: TAK-117 400 mg | Process A: TAK-117 600 mg | Process A: TAK-117 900 mg | Process A: TAK-117 1200 mg | Process B: TAK-117 300 mg | Process B: TAK-117 400 mg | Process B: TAK-117 500 mg | Process B: TAK-117 600 mg | Process B: TAK-117 900 mg | Process B: TAK-117 1200 mg | Process B: TAK-117 1500 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T 1/2z: Terminal Disposition Phase Half-life for TAK-117 | 8.74 ± 3.0 | 7.32 ± 3.3 | 11.17 ± 4.5 | 9.75 ± 5.5 | 12.24 ± 3.9 | 14.71 ± 6.4 | 11.12 ± 3.9 | 25.87 ± 22.7 | NA ± NA | NA ± NA | NA ± NA | 12.17 ± 4.0 | 8.34 ± 4.7 | 14.28 ± 3.5 | 9.53 ± 2.5 |
| nanogram hours per milliliter (ng*hr/mL) | Process A: TAK-117 100 mg | Process A: TAK-117 150 mg | Process A: TAK-117 200 mg | Process A: TAK-117 300 mg | Process A: TAK-117 400 mg | Process A: TAK-117 600 mg | Process A: TAK-117 900 mg | Process A: TAK-117 1200 mg | Process B: TAK-117 300 mg | Process B: TAK-117 400 mg | Process B: TAK-117 500 mg | Process B: TAK-117 600 mg | Process B: TAK-117 900 mg | Process B: TAK-117 1200 mg | Process B: TAK-117 1500 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-117 | 18008 ± 78.8 | 13807 ± 93.2 | 44733 ± 58.0 | 42909 ± 102.2 | 93748 ± 19.8 | 75937 ± 94.4 | 129217 ± 56.0 | 309073 ± 23.7 | NA ± NA | NA ± NA | NA ± NA | 62876 ± 78.4 | 84394 ± 103.1 | 164508 ± 74.9 | 87515 ± 81.2 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Pharmacodynamic markers included phosphorylated ribosomal protein S6 (PS6), phosphorylated eukaryotic initiation factor 4E-binding protein 1 (P4EBP1), phosphorylated N-myc downstream regulated gene 1 (PNDRG1), phosphorylated proline-rich AKT substrate of 40 kilodaltons (PPRAS40), and phosphorylated serine/threonine protein kinase AKT (PAKT). Analysis population (n) for each skin biopsy biomarker is as follow: P4EBP1 (n=6,6,6,2,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0); PAKT and PNDRG1 (n=6,6,7,2,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0); PPRAS40 (n= 6,0,6,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0); PS6 (n=6,6,7,2,2,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0)."n" for each tumor tissue biomarkers is as follow: P4EBP1, PAKT, PNDRG1, and PS6 (n=1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0); PPRAS40 (n= 1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0).
| percent change | Process A: TAK-117 100 Milligram (mg), Once Daily (QD) | Process A: TAK-117 150 mg, QD | Process A: TAK-117 200 mg, QD | Process A: TAK-117 300 mg, QD | Process A: TAK-117 200 mg, MWF QW | Process A: TAK-117 300 mg, MWF QW | Process A: TAK-117 400 mg, MWF QW | Process A: TAK-117 600 mg, MWF QW | Process A: TAK-117 900 mg, MWF QW | Process A: TAK-117 1200 mg, MWF QW | Process A: TAK-117 200 mg, MTW QW | Process A: TAK-117 400 mg, MTW QW | Process A: TAK-117 600 mg, MTW QW | Process A: TAK-117 900 mg, MTW QW | Process B: TAK-117 600 mg Process B Capsule (FM) MWF QW | Process B: TAK-117 900 mg FM MWF QW | Process B: TAK-117 1200 mg FM MWF QW | Process B: TAK-117 600 mg FM MTW QW | Process B: TAK-117 900 mg FM MTW QW | Process B: TAK-117 1200 mg FM MTW QW | Process B: TAK-117 1500 mg FM MTW QW | Process B: TAK-117 300 mg FM Twice Daily (BID) MWF QW | Process B: TAK-117 400 mg FM BID MWF QW | Process B: TAK-117 500 mg FM BID MWF QW | Process B: TAK-117 600 mg FM BID MWF QW |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Skin Biopsy: P4EBP1 | -27.94 ± 56.666 | -13.07 ± 39.758 | -61.41 ± 40.015 | -24.50 ± 54.388 | -100.00 ± 0.000 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | -100.00 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Skin Biopsy: PAKT | -11.59 ± 33.833 | 190.32 ± 257.212 | -30.02 ± 37.444 | -12.97 ± 5.896 | -18.75 ± 26.517 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 733.33 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Skin Biopsy: PNDRG1 | -9.82 ± 15.138 | -0.11 ± 35.915 | -10.11 ± 26.814 | -21.67 ± 35.355 | 10.69 ± 31.283 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | -34.44 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Skin Biopsy: PPRAS40 | 69.56 ± 272.327 | NA ± NA | -26.90 ± 37.191 | -18.75 ± 61.872 | -14.17 ± 8.250 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Skin Biopsy: PS6 | -15.23 ± 18.886 | -25.05 ± 15.883 | -11.88 ± 37.773 | 22.70 ± 24.462 | 9.54 ± 19.146 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 46.15 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Tumor Tissue: P4EBP1 | 236.00 ± NA | -97.56 ± NA | NA ± NA | NA ± NA | 7.48 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Tumor Tissue: PAKT | 850.00 ± NA | -20.87 ± NA | NA ± NA | NA ± NA | -44.83 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Tumor Tissue: PNDRG1 | 134.69 ± NA | -16.49 ± NA | NA ± NA | NA ± NA | 134.29 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Tumor Tissue: PPRAS40 | 196.83 ± NA | NA ± NA | NA ± NA | NA ± NA | 10.43 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Tumor Tissue: PS6 | 200.00 ± NA | 0.00 ± NA | NA ± NA | NA ± NA | -82.86 ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Process A: TAK-117 100 Milligram (mg), Once Daily (QD) | — | 2/6 (33.3%) | 6/6 (100%) |
| Process A: TAK-117 150 mg, QD | — | 3/6 (50%) | 6/6 (100%) |
| Process A: TAK-117 200 mg, QD | — | 4/8 (50%) | 8/8 (100%) |
| Process A: TAK-117 300 mg, QD | — | 2/4 (50%) | 4/4 (100%) |
| Process A: TAK-117 200 mg, MWF QW | — | 0/3 (0%) | 3/3 (100%) |
| Process A: TAK-117 300 mg, MWF QW | — | 2/3 (66.7%) | 3/3 (100%) |
| Process A: TAK-117 400 mg, MWF QW | — | 0/3 (0%) | 3/3 (100%) |
| Process A: TAK-117 600 mg, MWF QW | — | 2/3 (66.7%) | 3/3 (100%) |
| Process A: TAK-117 900 mg, MWF QW | — | 5/12 (41.7%) | 12/12 (100%) |
| Process A: TAK-117 1200 mg, MWF QW | — | 2/3 (66.7%) | 3/3 (100%) |
| Process A: TAK-117 200 mg, MTW QW | — | 0/3 (0%) | 3/3 (100%) |
| Process A: TAK-117 400 mg, MTW QW | — | 1/3 (33.3%) | 3/3 (100%) |
| Process A: TAK-117 600 mg, MTW QW | — | 0/3 (0%) | 3/3 (100%) |
| Process A: TAK-117 900 mg, MTW QW | — | 7/11 (63.6%) | 11/11 (100%) |
| Process B: TAK-117 600 mg Process B Capsule (FM) MWF QW | — | 1/3 (33.3%) | 3/3 (100%) |
| Process B: TAK-117 900 mg FM MWF QW | — | 2/3 (66.7%) | 3/3 (100%) |
| Process B: TAK-117 1200 mg FM MWF QW | — | 2/7 (28.6%) | 7/7 (100%) |
| Process B: TAK-117 600 mg FM MTW QW | — | 1/3 (33.3%) | 3/3 (100%) |
| Process B: TAK-117 900 mg FM MTW QW | — | 1/3 (33.3%) | 3/3 (100%) |
| Process B: TAK-117 1200 mg FM MTW QW | — | 1/3 (33.3%) | 3/3 (100%) |
| Process B: TAK-117 1500 mg FM MTW QW | — | 2/6 (33.3%) | 6/6 (100%) |
| Process B: TAK-117 300 mg FM Twice Daily (BID) MWF QW | — | 1/4 (25%) | 2/4 (50%) |
| Process B: TAK-117 400 mg FM BID MWF QW | — | 1/4 (25%) | 4/4 (100%) |
| Process B: TAK-117 500 mg FM BID MWF QW | — | 5/10 (50%) | 10/10 (100%) |
| Process B: TAK-117 600 mg FM BID MWF QW | — | 5/8 (62.5%) | 7/8 (87.5%) |
| Event | Process A: TAK-117 100 Milligram (mg), Once Daily (QD) | Process A: TAK-117 150 mg, QD | Process A: TAK-117 200 mg, QD | Process A: TAK-117 300 mg, QD | Process A: TAK-117 200 mg, MWF QW | Process A: TAK-117 300 mg, MWF QW | Process A: TAK-117 400 mg, MWF QW | Process A: TAK-117 600 mg, MWF QW | Process A: TAK-117 900 mg, MWF QW | Process A: TAK-117 1200 mg, MWF QW | Process A: TAK-117 200 mg, MTW QW | Process A: TAK-117 400 mg, MTW QW | Process A: TAK-117 600 mg, MTW QW | Process A: TAK-117 900 mg, MTW QW | Process B: TAK-117 600 mg Process B Capsule (FM) MWF QW | Process B: TAK-117 900 mg FM MWF QW | Process B: TAK-117 1200 mg FM MWF QW | Process B: TAK-117 600 mg FM MTW QW | Process B: TAK-117 900 mg FM MTW QW | Process B: TAK-117 1200 mg FM MTW QW | Process B: TAK-117 1500 mg FM MTW QW | Process B: TAK-117 300 mg FM Twice Daily (BID) MWF QW | Process B: TAK-117 400 mg FM BID MWF QW | Process B: TAK-117 500 mg FM BID MWF QW | Process B: TAK-117 600 mg FM BID MWF QW |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 1/6 | 0/6 | 0/8 | 0/4 | 0/3 | 0/3 | 0/3 | 1/3 | 0/12 | 1/3 | 0/3 | 0/3 | 0/3 | 0/11 | 0/3 | 0/3 | 0/7 | 0/3 | 1/3 | 0/3 | 0/6 | 0/4 | 0/4 | 0/10 | 1/8 |
| NauseaGastrointestinal disorders | 1/6 | 0/6 | 0/8 | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/12 | 1/3 | 0/3 | 0/3 | 0/3 | 0/11 | 0/3 | 0/3 | 0/7 | 0/3 | 0/3 | 0/3 | 1/6 | 0/4 | 0/4 | 0/10 | 0/8 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 0/6 | 0/8 | 0/4 | 0/3 | 0/3 | 0/3 | 1/3 | 0/12 | 1/3 | 0/3 | 0/3 | 0/3 | 0/11 | 0/3 | 0/3 | 0/7 | 0/3 | 0/3 | 0/3 | 0/6 | 0/4 | 0/4 | 0/10 | 0/8 |
| ColitisGastrointestinal disorders | 0/6 | 0/6 | 0/8 | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/12 | 0/3 | 0/3 | 0/3 | 0/3 | 0/11 | 0/3 | 0/3 | 0/7 | 1/3 | 0/3 | 0/3 | 0/6 | 0/4 | 0/4 | 0/10 | 0/8 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/6 | 0/6 | 0/8 | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/12 | 0/3 | 0/3 | 0/3 | 0/3 | 0/11 | 1/3 | 0/3 | 0/7 | 0/3 | 0/3 | 0/3 | 0/6 | 0/4 | 0/4 | 0/10 | 0/8 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/8 | 1/4 | 0/3 | 1/3 | 0/3 | 1/3 | 1/12 | 0/3 | 0/3 | 0/3 | 0/3 | 0/11 | 0/3 | 0/3 | 0/7 | 0/3 | 0/3 | 0/3 | 0/6 | 0/4 | 0/4 | 0/10 | 0/8 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/8 | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/12 | 1/3 | 0/3 | 0/3 | 0/3 | 0/11 | 0/3 | 0/3 | 1/7 | 0/3 | 0/3 | 0/3 | 0/6 | 0/4 | 0/4 | 0/10 | 0/8 |
| CellulitisInfections and infestations | 0/6 | 0/6 | 0/8 | 0/4 | 0/3 | 1/3 | 0/3 | 0/3 | 0/12 | 0/3 | 0/3 | 0/3 | 0/3 | 0/11 | 0/3 | 0/3 | 0/7 | 0/3 | 0/3 | 0/3 | 0/6 | 0/4 | 0/4 | 0/10 | 0/8 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/6 | 0/6 | 0/8 | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/12 | 1/3 | 0/3 | 0/3 | 0/3 | 0/11 | 0/3 | 0/3 | 1/7 | 0/3 | 0/3 | 0/3 | 0/6 | 0/4 | 0/4 | 2/10 | 0/8 |
| DehydrationMetabolism and nutrition disorders | 0/6 | 0/6 | 0/8 | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/12 | 1/3 | 0/3 | 0/3 | 0/3 | 0/11 | 0/3 | 0/3 | 0/7 | 0/3 | 0/3 | 0/3 | 0/6 | 0/4 | 0/4 | 0/10 | 0/8 |
| Event | Process A: TAK-117 100 Milligram (mg), Once Daily (QD) | Process A: TAK-117 150 mg, QD | Process A: TAK-117 200 mg, QD | Process A: TAK-117 300 mg, QD | Process A: TAK-117 200 mg, MWF QW | Process A: TAK-117 300 mg, MWF QW | Process A: TAK-117 400 mg, MWF QW | Process A: TAK-117 600 mg, MWF QW | Process A: TAK-117 900 mg, MWF QW | Process A: TAK-117 1200 mg, MWF QW | Process A: TAK-117 200 mg, MTW QW | Process A: TAK-117 400 mg, MTW QW | Process A: TAK-117 600 mg, MTW QW | Process A: TAK-117 900 mg, MTW QW | Process B: TAK-117 600 mg Process B Capsule (FM) MWF QW | Process B: TAK-117 900 mg FM MWF QW | Process B: TAK-117 1200 mg FM MWF QW | Process B: TAK-117 600 mg FM MTW QW | Process B: TAK-117 900 mg FM MTW QW | Process B: TAK-117 1200 mg FM MTW QW | Process B: TAK-117 1500 mg FM MTW QW | Process B: TAK-117 300 mg FM Twice Daily (BID) MWF QW | Process B: TAK-117 400 mg FM BID MWF QW | Process B: TAK-117 500 mg FM BID MWF QW | Process B: TAK-117 600 mg FM BID MWF QW |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 3/6 | 4/6 | 5/8 | 2/4 | 1/3 | 2/3 | 0/3 | 3/3 | 8/12 | 1/3 | 2/3 | 2/3 | 1/3 | 10/11 | 2/3 | 1/3 | 6/7 | 1/3 | 2/3 | 2/3 | 4/6 | 2/4 | 2/4 | 7/10 | 3/8 |
| StomatitisGastrointestinal disorders | 0/6 | 1/6 | 1/8 | 0/4 | 1/3 | 0/3 | 0/3 | 0/3 | 1/12 | 1/3 | 0/3 | 0/3 | 0/3 | 1/11 | 1/3 | 0/3 | 1/7 | 1/3 | 1/3 | 3/3 | 1/6 | 0/4 | 0/4 | 1/10 | 2/8 |
| FatigueGeneral disorders | 1/6 | 6/6 | 4/8 | 1/4 | 1/3 | 2/3 | 1/3 | 0/3 | 7/12 | 1/3 | 3/3 | 1/3 | 0/3 | 6/11 | 0/3 | 2/3 | 3/7 | 2/3 | 2/3 | 3/3 | 5/6 | 1/4 | 1/4 | 6/10 | 2/8 |
| DiarrhoeaGastrointestinal disorders | 1/6 | 3/6 | 5/8 | 3/4 | 0/3 | 1/3 | 2/3 | 1/3 | 6/12 | 1/3 | 0/3 | 0/3 | 2/3 | 8/11 | 0/3 | 2/3 | 5/7 | 0/3 | 1/3 | 1/3 | 4/6 | 2/4 | 2/4 | 3/10 | 3/8 |
| Decreased appetiteMetabolism and nutrition disorders | 1/6 | 1/6 | 4/8 | 2/4 | 1/3 | 2/3 | 1/3 | 2/3 | 2/12 | 2/3 | 1/3 | 1/3 | 0/3 | 4/11 | 0/3 | 1/3 | 4/7 | 1/3 | 0/3 | 1/3 | 3/6 | 1/4 | 3/4 | 6/10 | 1/8 |
| Aspartate aminotransferase increasedInvestigations | 1/6 | 3/6 | 4/8 | 3/4 | 2/3 | 2/3 | 1/3 | 0/3 | 4/12 | 1/3 | 1/3 | 0/3 | 1/3 | 2/11 | 1/3 | 0/3 | 0/7 | 1/3 | 1/3 | 2/3 | 2/6 | 1/4 | 1/4 | 1/10 | 3/8 |
| Alanine aminotransferase increasedInvestigations | 1/6 | 2/6 | 3/8 | 3/4 | 1/3 | 1/3 | 1/3 | 0/3 | 3/12 | 1/3 | 0/3 | 0/3 | 1/3 | 2/11 | 1/3 | 0/3 | 0/7 | 0/3 | 1/3 | 1/3 | 2/6 | 1/4 | 1/4 | 1/10 | 4/8 |
| VomitingGastrointestinal disorders | 2/6 | 1/6 | 4/8 | 1/4 | 2/3 | 2/3 | 0/3 | 2/3 | 8/12 | 2/3 | 2/3 | 1/3 | 2/3 | 7/11 | 0/3 | 2/3 | 5/7 | 1/3 | 2/3 | 0/3 | 4/6 | 2/4 | 1/4 | 7/10 | 5/8 |
| ConstipationGastrointestinal disorders | 1/6 | 4/6 | 3/8 | 1/4 | 1/3 | 0/3 | 1/3 | 2/3 | 4/12 | 1/3 | 1/3 | 1/3 | 0/3 | 4/11 | 0/3 | 0/3 | 2/7 | 1/3 | 1/3 | 2/3 | 2/6 | 0/4 | 2/4 | 1/10 | 0/8 |
| HyperglycaemiaMetabolism and nutrition disorders | 3/6 | 0/6 | 2/8 | 2/4 | 2/3 | 1/3 | 1/3 | 0/3 | 4/12 | 2/3 | 1/3 | 1/3 | 1/3 | 6/11 | 2/3 | 0/3 | 2/7 | 1/3 | 1/3 | 0/3 | 3/6 | 1/4 | 2/4 | 5/10 | 2/8 |
The all subjects as treated (ASaT) population included all enrolled participants who received at least 1 dose of TAK-117.
| Age, Continuous(years) | Process A: TAK-117 100 Milligram (mg), Once Daily (QD) | Process A: TAK-117 150 mg, QD | Process A: TAK-117 200 mg, QD | Process A: TAK-117 300 mg, QD | Process A: TAK-117 200 mg, MWF QW | Process A: TAK-117 300 mg, MWF QW | Process A: TAK-117 400 mg, MWF QW | Process A: TAK-117 600 mg, MWF QW | Process A: TAK-117 900 mg, MWF QW | Process A: TAK-117 1200 mg, MWF QW | Process A: TAK-117 200 mg, MTW QW | Process A: TAK-117 400 mg, MTW QW | Process A: TAK-117 600 mg, MTW QW | Process A: TAK-117 900 mg, MTW QW | Process B: TAK-117 600 mg Process B Capsule (FM) MWF QW | Process B: TAK-117 900 mg FM MWF QW | Process B: TAK-117 1200 mg FM MWF QW | Process B: TAK-117 600 mg FM MTW QW | Process B: TAK-117 900 mg FM MTW QW | Process B: TAK-117 1200 mg FM MTW QW | Process B: TAK-117 1500 mg FM MTW QW | Process B: TAK-117 300 mg FM Twice Daily (BID) MWF QW | Process B: TAK-117 400 mg FM BID MWF QW | Process B: TAK-117 500 mg FM BID MWF QW | Process B: TAK-117 600 mg FM BID MWF QW | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 64.7 ± 9.79 | 59.0 ± 10.88 | 59.3 ± 9.05 | 45.3 ± 7.27 | 56.3 ± 17.67 | 52.7 ± 14.01 | 54.3 ± 12.58 | 65.0 ± 13.11 | 56.4 ± 13.28 | 53.3 ± 19.40 | 64.7 ± 18.58 | 50.0 ± 11.53 | 55.0 ± 9.54 | 57.4 ± 10.88 | 65.7 ± 12.86 | 62.7 ± 16.17 | 61.0 ± 11.89 | 52.7 ± 19.76 | 53.7 ± 1.53 | 66.7 ± 2.52 | 61.3 ± 13.68 | 72.5 ± 4.65 | 60.3 ± 11.81 | 66.0 ± 8.71 | 59.5 ± 10.39 | 59.4 ± 11.89 |
| Gender(Participants) | Process A: TAK-117 100 Milligram (mg), Once Daily (QD) | Process A: TAK-117 150 mg, QD | Process A: TAK-117 200 mg, QD | Process A: TAK-117 300 mg, QD | Process A: TAK-117 200 mg, MWF QW | Process A: TAK-117 300 mg, MWF QW | Process A: TAK-117 400 mg, MWF QW | Process A: TAK-117 600 mg, MWF QW | Process A: TAK-117 900 mg, MWF QW | Process A: TAK-117 1200 mg, MWF QW | Process A: TAK-117 200 mg, MTW QW | Process A: TAK-117 400 mg, MTW QW | Process A: TAK-117 600 mg, MTW QW | Process A: TAK-117 900 mg, MTW QW | Process B: TAK-117 600 mg Process B Capsule (FM) MWF QW | Process B: TAK-117 900 mg FM MWF QW | Process B: TAK-117 1200 mg FM MWF QW | Process B: TAK-117 600 mg FM MTW QW | Process B: TAK-117 900 mg FM MTW QW | Process B: TAK-117 1200 mg FM MTW QW | Process B: TAK-117 1500 mg FM MTW QW | Process B: TAK-117 300 mg FM Twice Daily (BID) MWF QW | Process B: TAK-117 400 mg FM BID MWF QW | Process B: TAK-117 500 mg FM BID MWF QW | Process B: TAK-117 600 mg FM BID MWF QW | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 4 | 5 | 3 | 2 | 2 | 2 | 3 | 9 | 3 | 1 | 1 | 3 | 7 | 1 | 1 | 5 | 1 | 2 | 2 | 4 | 4 | 4 | 5 | 6 | 84 |
| Male | 2 | 2 | 3 | 1 | 1 | 1 | 1 | 0 | 3 | 0 | 2 | 2 | 0 | 4 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 0 | 0 | 5 | 2 | 41 |
| Ethnicity (NIH/OMB)(Participants) | Process A: TAK-117 100 Milligram (mg), Once Daily (QD) | Process A: TAK-117 150 mg, QD | Process A: TAK-117 200 mg, QD | Process A: TAK-117 300 mg, QD | Process A: TAK-117 200 mg, MWF QW | Process A: TAK-117 300 mg, MWF QW | Process A: TAK-117 400 mg, MWF QW | Process A: TAK-117 600 mg, MWF QW | Process A: TAK-117 900 mg, MWF QW | Process A: TAK-117 1200 mg, MWF QW | Process A: TAK-117 200 mg, MTW QW | Process A: TAK-117 400 mg, MTW QW | Process A: TAK-117 600 mg, MTW QW | Process A: TAK-117 900 mg, MTW QW | Process B: TAK-117 600 mg Process B Capsule (FM) MWF QW | Process B: TAK-117 900 mg FM MWF QW | Process B: TAK-117 1200 mg FM MWF QW | Process B: TAK-117 600 mg FM MTW QW | Process B: TAK-117 900 mg FM MTW QW | Process B: TAK-117 1200 mg FM MTW QW | Process B: TAK-117 1500 mg FM MTW QW | Process B: TAK-117 300 mg FM Twice Daily (BID) MWF QW | Process B: TAK-117 400 mg FM BID MWF QW | Process B: TAK-117 500 mg FM BID MWF QW | Process B: TAK-117 600 mg FM BID MWF QW | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Not Hispanic or Latino | 5 | 6 | 6 | 4 | 3 | 3 | 2 | 3 | 11 | 3 | 3 | 2 | 3 | 11 | 3 | 3 | 7 | 3 | 3 | 3 | 6 | 4 | 4 | 9 | 7 | 117 |
| Unknown or Not Reported | 1 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
| Race/Ethnicity, Customized(participants) | Process A: TAK-117 100 Milligram (mg), Once Daily (QD) | Process A: TAK-117 150 mg, QD | Process A: TAK-117 200 mg, QD | Process A: TAK-117 300 mg, QD | Process A: TAK-117 200 mg, MWF QW | Process A: TAK-117 300 mg, MWF QW | Process A: TAK-117 400 mg, MWF QW | Process A: TAK-117 600 mg, MWF QW | Process A: TAK-117 900 mg, MWF QW | Process A: TAK-117 1200 mg, MWF QW | Process A: TAK-117 200 mg, MTW QW | Process A: TAK-117 400 mg, MTW QW | Process A: TAK-117 600 mg, MTW QW | Process A: TAK-117 900 mg, MTW QW | Process B: TAK-117 600 mg Process B Capsule (FM) MWF QW | Process B: TAK-117 900 mg FM MWF QW | Process B: TAK-117 1200 mg FM MWF QW | Process B: TAK-117 600 mg FM MTW QW | Process B: TAK-117 900 mg FM MTW QW | Process B: TAK-117 1200 mg FM MTW QW | Process B: TAK-117 1500 mg FM MTW QW | Process B: TAK-117 300 mg FM Twice Daily (BID) MWF QW | Process B: TAK-117 400 mg FM BID MWF QW | Process B: TAK-117 500 mg FM BID MWF QW | Process B: TAK-117 600 mg FM BID MWF QW | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 6 | 6 | 8 | 3 | 3 | 2 | 1 | 3 | 12 | 3 | 3 | 1 | 3 | 11 | 2 | 2 | 7 | 3 | 3 | 3 | 6 | 3 | 3 | 10 | 8 | 115 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 4 |
| Asian | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 |
| Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Female Child Bearing Potential(participants) | Process A: TAK-117 100 Milligram (mg), Once Daily (QD) | Process A: TAK-117 150 mg, QD | Process A: TAK-117 200 mg, QD | Process A: TAK-117 300 mg, QD | Process A: TAK-117 200 mg, MWF QW | Process A: TAK-117 300 mg, MWF QW | Process A: TAK-117 400 mg, MWF QW | Process A: TAK-117 600 mg, MWF QW | Process A: TAK-117 900 mg, MWF QW | Process A: TAK-117 1200 mg, MWF QW | Process A: TAK-117 200 mg, MTW QW | Process A: TAK-117 400 mg, MTW QW | Process A: TAK-117 600 mg, MTW QW | Process A: TAK-117 900 mg, MTW QW | Process B: TAK-117 600 mg Process B Capsule (FM) MWF QW | Process B: TAK-117 900 mg FM MWF QW | Process B: TAK-117 1200 mg FM MWF QW | Process B: TAK-117 600 mg FM MTW QW | Process B: TAK-117 900 mg FM MTW QW | Process B: TAK-117 1200 mg FM MTW QW | Process B: TAK-117 1500 mg FM MTW QW | Process B: TAK-117 300 mg FM Twice Daily (BID) MWF QW | Process B: TAK-117 400 mg FM BID MWF QW | Process B: TAK-117 500 mg FM BID MWF QW | Process B: TAK-117 600 mg FM BID MWF QW | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Females of Child-bearing Potential | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 7 |
| Post-menopausal | 4 | 3 | 3 | 0 | 1 | 1 | 1 | 1 | 4 | 2 | 0 | 0 | 2 | 2 | 0 | 1 | 4 | 1 | 2 | 1 | 4 | 4 | 3 | 3 | 4 | 51 |
| Sterilized Females | 0 | 1 | 1 | 2 | 0 | 1 | 1 | 2 | 4 | 1 | 1 | 0 | 1 | 5 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 26 |
| Males (Excluded from this analysis) | 2 | 2 | 3 | 1 | 1 | 1 | 1 | 0 | 3 | 0 | 2 | 2 | 0 | 4 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 0 | 0 | 5 | 2 | 41 |
| Height(centimeter (cm)) | Process A: TAK-117 100 Milligram (mg), Once Daily (QD) | Process A: TAK-117 150 mg, QD | Process A: TAK-117 200 mg, QD | Process A: TAK-117 300 mg, QD | Process A: TAK-117 200 mg, MWF QW | Process A: TAK-117 300 mg, MWF QW | Process A: TAK-117 400 mg, MWF QW | Process A: TAK-117 600 mg, MWF QW | Process A: TAK-117 900 mg, MWF QW | Process A: TAK-117 1200 mg, MWF QW | Process A: TAK-117 200 mg, MTW QW | Process A: TAK-117 400 mg, MTW QW | Process A: TAK-117 600 mg, MTW QW | Process A: TAK-117 900 mg, MTW QW | Process B: TAK-117 600 mg Process B Capsule (FM) MWF QW | Process B: TAK-117 900 mg FM MWF QW | Process B: TAK-117 1200 mg FM MWF QW | Process B: TAK-117 600 mg FM MTW QW | Process B: TAK-117 900 mg FM MTW QW | Process B: TAK-117 1200 mg FM MTW QW | Process B: TAK-117 1500 mg FM MTW QW | Process B: TAK-117 300 mg FM Twice Daily (BID) MWF QW | Process B: TAK-117 400 mg FM BID MWF QW | Process B: TAK-117 500 mg FM BID MWF QW | Process B: TAK-117 600 mg FM BID MWF QW | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 161.70 ± 10.758 | 164.29 ± 7.241 | 165.25 ± 9.403 | 164.15 ± 5.837 | 164.19 ± 5.195 | 161.81 ± 5.222 | 165.17 ± 7.848 | 163.49 ± 6.883 | 163.08 ± 12.871 | 158.76 ± 9.161 | 168.76 ± 2.043 | 173.43 ± 6.072 | 164.67 ± 3.055 | 167.46 ± 10.274 | 170.22 ± 1.683 | 168.93 ± 16.176 | 168.32 ± 4.243 | 169.83 ± 13.829 | 169.52 ± 8.713 | 168.11 ± 6.887 | 165.97 ± 6.472 | 159.00 ± 3.939 | 157.05 ± 3.316 | 168.79 ± 13.186 | 164.87 ± 9.638 | 165.49 ± 9.098 |
| Weight(kilogram (kg)) | Process A: TAK-117 100 Milligram (mg), Once Daily (QD) | Process A: TAK-117 150 mg, QD | Process A: TAK-117 200 mg, QD | Process A: TAK-117 300 mg, QD | Process A: TAK-117 200 mg, MWF QW | Process A: TAK-117 300 mg, MWF QW | Process A: TAK-117 400 mg, MWF QW | Process A: TAK-117 600 mg, MWF QW | Process A: TAK-117 900 mg, MWF QW | Process A: TAK-117 1200 mg, MWF QW | Process A: TAK-117 200 mg, MTW QW | Process A: TAK-117 400 mg, MTW QW | Process A: TAK-117 600 mg, MTW QW | Process A: TAK-117 900 mg, MTW QW | Process B: TAK-117 600 mg Process B Capsule (FM) MWF QW | Process B: TAK-117 900 mg FM MWF QW | Process B: TAK-117 1200 mg FM MWF QW | Process B: TAK-117 600 mg FM MTW QW | Process B: TAK-117 900 mg FM MTW QW | Process B: TAK-117 1200 mg FM MTW QW | Process B: TAK-117 1500 mg FM MTW QW | Process B: TAK-117 300 mg FM Twice Daily (BID) MWF QW | Process B: TAK-117 400 mg FM BID MWF QW | Process B: TAK-117 500 mg FM BID MWF QW | Process B: TAK-117 600 mg FM BID MWF QW | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 62.18 ± 6.403 | 71.15 ± 21.862 | 73.48 ± 9.159 | 67.65 ± 24.513 | 72.48 ± 17.665 | 61.54 ± 2.487 | 57.73 ± 0.462 | 63.41 ± 3.880 | 69.14 ± 15.486 | 65.03 ± 15.137 | 70.76 ± 16.458 | 83.39 ± 28.852 | 60.60 ± 9.016 | 73.78 ± 12.955 | 72.26 ± 11.235 | 75.22 ± 12.679 | 79.84 ± 16.648 | 81.07 ± 25.417 | 82.72 ± 17.982 | 62.61 ± 15.706 | 64.59 ± 16.477 | 73.65 ± 16.747 | 65.37 ± 11.853 | 70.51 ± 15.263 | 65.11 ± 9.599 | 70.17 ± 14.958 |
| Body Surface Area (BSA)(square meter (m^2)) | Process A: TAK-117 100 Milligram (mg), Once Daily (QD) | Process A: TAK-117 150 mg, QD | Process A: TAK-117 200 mg, QD | Process A: TAK-117 300 mg, QD | Process A: TAK-117 200 mg, MWF QW | Process A: TAK-117 300 mg, MWF QW | Process A: TAK-117 400 mg, MWF QW | Process A: TAK-117 600 mg, MWF QW | Process A: TAK-117 900 mg, MWF QW | Process A: TAK-117 1200 mg, MWF QW | Process A: TAK-117 200 mg, MTW QW | Process A: TAK-117 400 mg, MTW QW | Process A: TAK-117 600 mg, MTW QW | Process A: TAK-117 900 mg, MTW QW | Process B: TAK-117 600 mg Process B Capsule (FM) MWF QW | Process B: TAK-117 900 mg FM MWF QW | Process B: TAK-117 1200 mg FM MWF QW | Process B: TAK-117 600 mg FM MTW QW | Process B: TAK-117 900 mg FM MTW QW | Process B: TAK-117 1200 mg FM MTW QW | Process B: TAK-117 1500 mg FM MTW QW | Process B: TAK-117 300 mg FM Twice Daily (BID) MWF QW | Process B: TAK-117 400 mg FM BID MWF QW | Process B: TAK-117 500 mg FM BID MWF QW | Process B: TAK-117 600 mg FM BID MWF QW | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 1.67 ± 0.108 | 1.78 ± 0.266 | 1.83 ± 0.152 | 1.85 ± 0.500 | 1.81 ± 0.241 | 1.66 ± 0.060 | 1.63 ± 0.041 | 1.70 ± 0.063 | 1.76 ± 0.248 | 1.69 ± 0.192 | 1.81 ± 0.209 | 1.99 ± 0.354 | 1.66 ± 0.110 | 1.85 ± 0.214 | 1.85 ± 0.151 | 1.88 ± 0.235 | 1.92 ± 0.210 | 1.95 ± 0.384 | 1.97 ± 0.262 | 1.70 ± 0.250 | 1.72 ± 0.253 | 1.80 ± 0.217 | 1.68 ± 0.154 | 1.82 ± 0.256 | 1.71 ± 0.170 | 1.79 ± 0.219 |
The record gives a start of Oct 2011, a primary completion of Jul 2015 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Serabelisib
Millennium Pharmaceuticals, Inc. →